Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics
TRVI Price/Volume Stats
| Current price | $2.24 | 52-week high | $3.50 |
| Prev. close | $2.18 | 52-week low | $1.43 |
| Day low | $2.20 | Volume | 3,956 |
| Day high | $2.24 | Avg. volume | 172,147 |
| 50-day MA | $2.26 | Dividend yield | N/A |
| 200-day MA | $2.33 | Market Cap | 143.03M |
TRVI Stock Price Chart Interactive Chart >
Trevi Therapeutics, Inc. (TRVI) Company Bio
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
Latest TRVI News From Around the Web
Below are the latest news stories about TREVI THERAPEUTICS INC that investors may wish to consider to help them evaluate TRVI as an investment opportunity.
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
Q2 2023 Trevi Therapeutics Inc Earnings CallQ2 2023 Trevi Therapeutics Inc Earnings Call |
Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business UpdateTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced financial results for the quarter ended June 30, 2023, as well as provided business updates. |
Trevi Therapeutics to Report Q2 2023 Financial Results and Provide a Corporate Update on August 10, 2023Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced that senior management will host a conference call and live audio webcast on Thursday, August 10, 2023, at 4:30 p.m. ET, to provide a corporate update and review the Company's financia |
Trevi Therapeutics to Participate in Upcoming August EventsTrevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced senior management will attend and participate in the following events in August. |
TRVI Price Returns
| 1-mo | -0.88% |
| 3-mo | -1.75% |
| 6-mo | 21.08% |
| 1-year | 28.00% |
| 3-year | -42.56% |
| 5-year | N/A |
| YTD | 16.06% |
| 2022 | 146.74% |
| 2021 | -67.68% |
| 2020 | -35.47% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...